XT
KPTI icon

XTX Topco’s Karyopharm Therapeutics KPTI Stock Holding History

XTX Topco’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$916K Buy
164,443
+152,539
+1,281% +$1.16M 0.02% 1487
2025
Q4 		$87.6K Sell
11,904
-2,498
-17% -$15.3K ﹤0.01% 2670
2025
Q3 		$94.2K Buy
14,402
+1,346
+10% +$7.24K ﹤0.01% 2034
2025
Q2 		$56.3K Buy
+13,056
New +$64.1K ﹤0.01% 1997
2024
Q4 		– Sell
-1,727
Closed -$21.5K – 2622
2024
Q3 		$21.5K Sell
1,727
-7,645
-82% -$95K ﹤0.01% 1832
2024
Q2 		$122K Sell
9,372
-6,817
-42% -$113K 0.01% 1372
2024
Q1 		$367K Buy
16,189
+12,914
+394% +$226K 0.05% 679
2023
Q4 		$42.5K Sell
3,275
-17,396
-84% -$234K 0.01% 1256
2023
Q3 		$415K Sell
20,671
-4,919
-19% -$110K 0.07% 510
2023
Q2 		$687K Buy
+25,590
New +$1.1M 0.12% 218
2023
Q1 		– Sell
-8,721
Closed -$445K – 1476
2022
Q4 		$445K Buy
8,721
+6,018
+223% +$417K 0.09% 356
2022
Q3 		$221K Sell
2,703
-737
-21% -$55K 0.05% 722
2022
Q2 		$233K Buy
3,440
+2,478
+258% +$227K 0.1% 400
2022
Q1 		$106K Buy
962
+92
+11% +$11.5K 0.05% 504
2021
Q4 		$84K Sell
870
-215
-20% -$21.4K 0.05% 495
2021
Q3 		$95K Buy
+1,085
New +$113K 0.03% 568

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

XTX Topco's KPTI Position: Q1 2026 in Review

XTX Topco increased its Karyopharm Therapeutics (KPTI) stake by 1,281% in Q1 2026, buying an estimated $1.16M and bringing the position to 164,443 shares worth $916K. The position accounts for 0.02% of the portfolio, ranked #1487.

XTX Topco first reported a position in KPTI in Q3 2021 and has held it in 16 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • XTX Topco held 164,443 shares of Karyopharm Therapeutics worth $916K as of Q1 2026.
  • XTX Topco bought 152,539 Karyopharm Therapeutics shares in Q1 2026, an estimated $1.16M.
  • Karyopharm Therapeutics made up 0.02% of XTX Topco's portfolio in Q1 2026, its #1487 holding.
  • XTX Topco first reported a position in Karyopharm Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.